Eli Lilly (LLY) is to acquire Orna Therapeutics. Acquisition valued at USD 2.4bln.

Eli Lilly's acquisition of Orna Therapeutics for USD 2.4 billion marks a significant move in the biotech sector, reflecting confidence in innovative therapies.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Newsquawk Daily US Conference Calendar - 9th February 2026: ICE, IBKR, KKR, MRSH

US PRE-MARKET MOVERS: Mag-7, KR, NXST/TGNA, LLY, XYZ, META, CLF, BDX, HIMS/NVO

Eli Lilly (LLY) is to acquire Orna Therapeutics. Acquisition valued at USD 2.4bln.

[MARKET UPDATE] Sterling continues to climb, Cable at a fresh session high, after UK PM Starmer says he will not resign

Iran's Atomic Chief Eslami says Tehran could dilute its highly enriched uranium if all sanctions are lifted, ISNA reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This deal could enhance Eli Lilly's pipeline and competitive position, but investors will want to assess its strategic fit and any integration risks. Overall, this acquisition might lead to increased interest in Pharmaceutical equities, particularly those involved in similar biotech space.

Related headlines

The whole workspace, free to try.

Try it free